Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07528716 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy

Name: Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy — clinical trial record (NCT07528716)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorFudan University

Started2026-05-06

View on ClinicalTrials.gov ↗

Amendment history

2026-07-05

Study Status, Contacts/Locations v1

Recruitment opened

Start dateestimated 2026-05→confirmed 2026-05-06

Study sitesdetails revised at 1 of 1 site

2026-04-09

Original filing

Fudan University

624 trials monitored

See 9 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

Based on total pathologic complete response (tpCR) after surgery, to evaluate the efficacy of an artificial intelligence model-matched anti-HER2 targeted treatment strategy (investigational arm) versus nab-paclitaxel + carboplatin + trastuzumab + pertuzumab (PCbHP, control arm) as neoadjuvant therapy for patients with early or locally advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Trial Details

NCT Number	NCT07528716
Lead Sponsor	Fudan University
Conditions	Breast Cancer
Enrollment	280 participants
Start Date	2026-05-06
Primary Completion	2027-12 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-08